Literature DB >> 10981138

Studies examining risk reduction in subjects with multiple metabolic and cardiovascular risk factors.

M L Tuck1, D B Corry.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 10981138     DOI： 10.1007/s11906-000-0071-6

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN： 1522-6417            Impact factor:   5.369


× No keyword cloud information.
  9 in total

1.  Vitamin E supplementation and cardiovascular events in high-risk patients.

Authors:  S Yusuf; G Dagenais; J Pogue; J Bosch; P Sleight
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Protective effect of captopril on the blood-retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy.

Authors:  M Larsen; E Hommel; H H Parving; H Lund-Andersen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

4.  Angiotensin-converting enzyme inhibitor therapy and diabetic retinopathy.

Authors:  W E Jackson; D L Holmes; S K Garg; S Harris; H P Chase
Journal:  Ann Ophthalmol       Date:  1992-03

5.  Angiotensin levels in the eye.

Authors:  A H Danser; F H Derkx; P J Admiraal; J Deinum; P T de Jong; M A Schalekamp
Journal:  Invest Ophthalmol Vis Sci       Date:  1994-03       Impact factor: 4.799

6.  Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus.

Authors:  N Chaturvedi; A K Sjolie; J M Stephenson; H Abrahamian; M Keipes; A Castellarin; Z Rogulja-Pepeonik; J H Fuller
Journal:  Lancet       Date:  1998-01-03       Impact factor: 79.321

7.  Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group.

Authors: 
Journal:  Lancet       Date:  1997-06-21       Impact factor: 79.321

8.  Angiotensin-converting enzyme inhibitor treatment for young normotensive diabetic subjects: a two-year trial.

Authors:  H P Chase; S K Garg; S Harris; S Hoops; W E Jackson; D L Holmes
Journal:  Ann Ophthalmol       Date:  1993-08

9.  Improvements in blood pressure, glucose metabolism, and lipoprotein lipids after aerobic exercise plus weight loss in obese, hypertensive middle-aged men.

Authors:  D R Dengel; J M Hagberg; R E Pratley; E M Rogus; A P Goldberg
Journal:  Metabolism       Date:  1998-09       Impact factor: 8.694
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.